Christian Kratz

List of Publications by Year
in descending order

83 papers	7,454 citations	147566 31 h-index	62479 80 g-index
110 all docs	110 docs citations	110 times ranked	9743 citing authors

#	Article	IF	Citations
1	Cancer in Children With Fanconi Anemia and Ataxia-Telangiectasiaâ€"A Nationwide Register-Based Cohort Study in Germany. Journal of Clinical Oncology, 2022, 40, 32-39.	0.8	17
2	The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute. Cell Death and Differentiation, 2022, 29, 1071-1073.	5.0	53
3	A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era. Cancer Discovery, 2022, 12, 331-355.	7.7	70
4	SMARCB1-deficient and SMARCA4-deficient Malignant Brain Tumors With Complex Copy Number Alterations and TP53 Mutations May Represent the First Clinical Manifestation of Li-Fraumeni Syndrome. American Journal of Surgical Pathology, 2022, 46, 1277-1283.	2.1	3
5	MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) andin vivo validation. Neuro-Oncology, 2022, 24, i168-i169.	0.6	0
6	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. Neuro-Oncology, 2022, 24, i107-i107.	0.6	1
7	ATRT-08. SMARCB1- and SMARCA4-deficient malignant brain tumors with complex copy number alterations andTP53 mutations may represent the first clinical manifestation of Li-Fraumeni syndrome. Neuro-Oncology, 2022, 24, i4-i4.	0.6	0
8	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/DendriticÂNeoplasms. Leukemia, 2022, 36, 1703-1719.	3.3	1,211
9	Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working Group. Familial Cancer, 2021, 20, 327-336.	0.9	13
10	Gastrointestinal Hemorrhage: A Manifestation of the Telomere Biology Disorders. Journal of Pediatrics, 2021, 230, 55-61.e4.	0.9	14
11	Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. Acta Neuropathologica, 2021, 141, 85-100.	3.9	52
12	Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group. Familial Cancer, 2021, 20, 305-316.	0.9	20
13	Proportion of children with cancer that have an indication for genetic counseling and testing based on the cancer type irrespective of other features. Familial Cancer, 2021, 20, 273-277.	0.9	9
14	Choose and stay on one out of two paths: distinction between clinical versus research genetic testing to identify cancer predisposition syndromes among patients with cancer. Familial Cancer, 2021, 20, 289-291.	0.9	5
15	Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Liâ€"Fraumeni syndrome. Leukemia, 2021, 35, 1475-1479.	3.3	17
16	Predisposition to cancer in children and adolescents. The Lancet Child and Adolescent Health, 2021, 5, 142-154.	2.7	53
17	Effective identification of cancer predisposition syndromes in children with cancer employing a questionnaire. Familial Cancer, 2021, 20, 257-262.	0.9	15
18	Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia. Leukemia, 2021, 35, 2650-2657.	3.3	13

#	Article	IF	Citations
19	Eye Tumors in Childhood as First Sign of Tumor Predisposition Syndromes: Insights from an Observational Study Conducted in Germany and Austria. Cancers, 2021, 13, 1876.	1.7	7
20	Current recommendations for cancer surveillance in Gorlin syndrome: a report from the SIOPE host genome working group (SIOPE HGWG). Familial Cancer, 2021, 20, 317-325.	0.9	22
21	A novel classification of hematologic conditions in patients with Fanconi anemia. Haematologica, 2021, 106, 3000-3003.	1.7	14
22	Unusual phenotypes in patients with a pathogenic germline variant in DICER1. Familial Cancer, 2021, , 1.	0.9	5
23	Wilms tumour surveillance in at-risk children: Literature review and recommendations from the SIOP-Europe Host Genome Working Group and SIOP Renal Tumour Study Group. European Journal of Cancer, 2021, 153, 51-63.	1.3	25
24	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. Journal of Clinical Oncology, 2021, 39, 2779-2790.	0.8	40
25	Breast cancer characteristics and surgery among women with Liâ€Fraumeni syndrome in Germanyâ€”A retrospective cohort study. Cancer Medicine, 2021, 10, 7747-7758.	1.3	7
26	Genetic Variation in ABCC4 and CFTR and Acute Pancreatitis during Treatment of Pediatric Acute Lymphoblastic Leukemia. Journal of Clinical Medicine, 2021, 10, 4815.	1.0	2
27	Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set. JAMA Oncology, 2021, 7, 1800.	3.4	55
28	First Report of Glioblastoma and Associated PNKP Mutation. Neuropediatrics, 2021, 52, .	0.3	0
29	Corrigendum to: Clinical spectrum and management of imprinting disorders. Medizinische Genetik, 2021, 33, 61-63.	0.1	0
30	Cancer surveillance for individuals with Li-Fraumeni syndrome. European Journal of Human Genetics, 2020, 28, 1481-1482.	1.4	7
31	Need for a precise molecular diagnosis in Beckwith-Wiedemann and Silver-Russell syndrome: what has to be considered and why it is important. Journal of Molecular Medicine, 2020, 98, 1447-1455.	1.7	15
32	Cancer incidence and spectrum among children with genetically confirmed Beckwith-Wiedemann spectrum in Germany: a retrospective cohort study. British Journal of Cancer, 2020, 123, 619-623.	2.9	30
33	High-sensitivity microsatellite instability assessment for the detection of mismatch repair defects in normal tissue of biallelic germline mismatch repair mutation carriers. Journal of Medical Genetics, 2020, 57, 269-273.	1.5	20
34	Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 927-935.	1.1	7
35	Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey. Cancer, 2020, 126, 4032-4041.	2.0	20
36	Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell Biology. Cancers, 2020, 12, 611.	1.7	23

#	Article	IF	Citations
37	Social inequalities in the participation and activity of children and adolescents with leukemia, brain tumors, and sarcomas (SUPATEEN): a protocol for a multicenter longitudinal prospective observational study. BMC Pediatrics, 2020, 20, 48.	0.7	3
38	TIMâ€3 deficiency presenting with two clonally unrelated episodes of mesenteric and subcutaneous panniculitisâ€like Tâ€cell lymphoma and hemophagocytic lymphohistiocytosis. Pediatric Blood and Cancer, 2020, 67, e28302.	0.8	17
39	Clinical spectrum and management of imprinting disorders. Medizinische Genetik, 2020, 32, 321-334.	0.1	5
40	MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathologica, 2019, 138, 1075-1089.	3.9	104
41	Neoplasm Risk Among Individuals With a Pathogenic Germline Variant in DICER1. Journal of Clinical Oncology, 2019, 37, 668-676.	0.8	107
42	A sensitive and scalable microsatellite instability assay to diagnose constitutional mismatch repair deficiency by sequencing of peripheral blood leukocytes. Human Mutation, 2019, 40, 649-655.	1.1	30
43	Medulloblastoma. Nature Reviews Disease Primers, 2019, 5, 11.	18.1	376
44	TP53, ETV6 and RUNX1 germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemia. Haematologica, 2019, 104, e402-e405.	1.7	6
45	Understanding the evolving phenotype of vascular complications in telomere biology disorders. Angiogenesis, 2019, 22, 95-102.	3.7	45
46	Constitutional mismatch repair deficiency as a differential diagnosis of neurofibromatosis type 1: consensus guidelines for testing a child without malignancy. Journal of Medical Genetics, 2019, 56, 53-62.	1.5	40
47	The landscape of genomic alterations across childhood cancers. Nature, 2018, 555, 321-327.	13.7	1,068
48	Revisiting Wilms tumour surveillance in Beckwithâ€“Wiedemann syndrome with IC2 methylation loss, reply. European Journal of Human Genetics, 2018, 26, 471-472.	1.4	13
49	Clinical and molecular diagnosis, screening and management of Beckwithâ€“Wiedemann syndrome: an international consensus statement. Nature Reviews Endocrinology, 2018, 14, 229-249.	4.3	388
50	KBG syndrome patient due to 16q24.3 microdeletion presenting with a paratesticular rhabdoid tumor: Coincidence or cancer predisposition?. American Journal of Medical Genetics, Part A, 2018, 176, 1449-1454.	0.7	6
51	IKZF1^{plus} Defines a New Minimal Residual Diseaseâ€“Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2018, 36, 1240-1249.	0.8	194
52	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncology, The, 2018, 19, 785-798.	5.1	268
53	Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD). European Journal of Human Genetics, 2018, 26, 1417-1423.	1.4	20
54	Inherited Disorders of the Ras-MAPK Pathway. Blood, 2018, 132, SCI-41-SCI-41.	0.6	1

#	Article	IF	Citations
55	Childhood cancer predisposition syndromesâ€"A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. American Journal of Medical Genetics, Part A, 2017, 173, 1017-1037.	0.7	200
56	Down syndrome, RASopathies, and other rare syndromes. Seminars in Hematology, 2017, 54, 123-128.	1.8	5
57	Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk. Clinical Cancer Research, 2017, 23, e83-e90.	3.2	122
58	Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clinical Cancer Research, 2017, 23, e38-e45.	3.2	358
59	Clinical Management and Tumor Surveillance Recommendations of Inherited Mismatch Repair Deficiency in Childhood. Clinical Cancer Research, 2017, 23, e32-e37.	3.2	157
60	Prognostic impact of IKZF1 deletions in association with vincristineâ€"dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95. Leukemia, 2017, 31, 1840-1842.	3.3	18
61	Comprehensive Analysis of Hypermutation in Human Cancer. Cell, 2017, 171, 1042-1056.e10.	13.5	596
62	Mutational Spectrum of Fanconi Anemia Associated Myeloid Neoplasms. Klinische Padiatrie, 2017, 229, 329-334.	0.2	13
63	Congenital Transcobalamin II Deficiency: A Rare Entity with a Broad Differential. Klinische Padiatrie, 2017, 229, 355-357.	0.2	6
64	Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood. Clinical Cancer Research, 2017, 23, e107-e114.	3.2	91
65	Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clinical Cancer Research, 2017, 23, e123-e132.	3.2	55
66	A novel germline POLE mutation causes an early onset cancer prone syndrome mimicking constitutional mismatch repair deficiency. Familial Cancer, 2017, 16, 67-71.	0.9	52
67	Correction: Congenital Transcobalamin II Deficiency: A Rare Entity with a Broad Differential. Klinische Padiatrie, 2017, 229, e1-e1.	0.2	0
68	TP53, ETV6 and RUNX1 Germline Variants in Patients Developing Secondary Neoplasms after Treatment for Childhood Acute Lymphoblastic Leukemia. Blood, 2017, 130, 884-884.	0.6	1
69	Hematologic Response to Vorinostat Treatment in Relapsed Myeloid Leukemia of Down Syndrome. Pediatric Blood and Cancer, 2016, 63, 1677-1679.	0.8	18
70	Diagnosis and Treatment of Nasopharyngeal Carcinoma in Children and Adolescents â€" Recommendations of the GPOH-NPC Study Group. Klinische Padiatrie, 2016, 228, 105-112.	0.2	44
71	Clinical utility gene card for: Familial platelet disorder with associated myeloid malignancies. European Journal of Human Genetics, 2016, 24, 3-4.	1.4	5
72	PMS2 inactivation by a complex rearrangement involving an HERV retroelement and the inverted 100-kb duplicon on 7p22.1. European Journal of Human Genetics, 2016, 24, 1598-1604.	1.4	9

#	Article	IF	Citations
73	Androgen therapy in Fanconi anemia: A retrospective analysis of 30 years in Germany. Pediatric Hematology and Oncology, 2016, 33, 5-12.	0.3	48
74	Genetic predisposition to acute lymphoblastic leukemia: Overview on behalf of the I-BFM ALL Host Genetic Variation Working Group. European Journal of Medical Genetics, 2016, 59, 111-115.	0.7	23
75	Preexisting conditions in pediatric ALL patients: Spectrum, frequency and clinical impact. European Journal of Medical Genetics, 2016, 59, 143-151.	0.7	22
76	Constitutional or biallelic? Settling on a name for a recessively inherited cancer susceptibility syndrome. Journal of Medical Genetics, 2016, 53, 226-226.	1.5	3
77	Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes. British Journal of Cancer, 2015, 112, 1392-1397.	2.9	167
78	Genomics and drug profiling of fatal TCF3-HLFâ˚positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nature Genetics, 2015, 47, 1020-1029.	9.4	190
79	Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium â€œCare for CMMR-Dâ€•(C4CMMR-D). Journal of Medical Genetics, 2014, 51, 283-293.	1.5	168
80	Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium â€˜Care for CMMRDâ€™ (C4CMMRD). Journal of Medical Genetics, 2014, 51, 355-365.	1.5	351
81	The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5, CDKN2A, CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1plus) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment. Blood, 2014, 124, 131-131.	0.6	4
82	SCT for Secondary AML in a Patient with Glycogen Storage Disease Type 1b. Blood, 2012, 120, 4402-4402.	0.6	1
83	Constitutional mismatch repair-deficiency syndrome. Haematologica, 2010, 95, 699-701.	1.7	141